Quoin Pharmaceuticals Advances QRX003 for Netherton Syndrome with Orphan Drug Designation in Europe
20/5 13:43
Quoin Pharmaceuticals announces Orphan Drug Designation for QRX003, providing potential 10-year market exclusivity in Europe for Netherton Syndrome....